AI Drug Discovery
Choose your target on evidence, not on the loudest paper
USD 45–120K · 6–10 weeks · Ranked shortlist with evidence dossiers · Optional wet-lab validation add-on
At a glance
- Price band
- USD 45–120K
- Duration
- 6–10 weeks
- Deliverable
- Ranked shortlist + dossiers
- Add-on
- Wet-lab validation
Indicative list price. Final scope and price confirmed in the proposal.
Talk to a scientistThe problem
Why teams buy this
Teams commit years and millions to targets chosen on incomplete evidence, then discover tractability or safety problems after the spend. The cost of choosing wrong is not measured in dollars - it is measured in quarters, and in the funding round you did not raise.
What you get
Deliverables, not activity
- A ranked target list with transparent, inspectable scoring - no black boxes
- An evidence dossier per target: genetic association, expression, pathway context, perturbation data
- A druggability and tractability assessment
- A competitive and IP landscape summary
- A recommended validation plan, costed
How it works
The sequence
- 01
Indication framing and agreement on evidence sources
- 02
Multi-omics and literature evidence assembly
- 03
Network and pathway analysis with genetic-association weighting
- 04
Druggability and tractability scoring
- 05
Ranked shortlist with dossiers
- 06
Optional: wet-lab validation of the top three to five targets (+8–12 weeks)
Who this is for
Emerging biotech choosing a lead programme · pharma discovery units entering a new therapeutic area · academic translational centres preparing to spin out · disease foundations directing research funding.
Proof
Representative result
Forty candidate targets in fibrosis narrowed to a defensible top five in seven weeks, with wet-lab confirmation of expression and knockdown phenotype for the leading two.
Representative programme - illustrates typical scope and outcomes; not an individual client account. Client-specific references are available on request under confidentiality.
Next
What we would suggest next
Questions we get asked
The awkward ones, answered
How is this different from a literature review?
A literature review tells you what has been published. This tells you what the combined evidence supports, weighted, scored and reproducible - and then tests it.
Can we see the scoring logic?
Yes. Transparent scoring is the deliverable. If you cannot interrogate the ranking, you cannot defend it to your board.
Do we have to buy the validation?
No. It is an add-on, and we will tell you honestly whether your shortlist needs it.
Enterprise AI for Life Sciences
Ready to Advance Your Drug Discovery Pipeline?
Partner with Prognica Labs to leverage enterprise-grade AI, computational chemistry, and molecular simulation technologies that accelerate discovery, reduce development risk, and improve R&D productivity.
From biotech startups to global pharmaceutical organizations, we help research teams make faster, evidence-driven decisions across every stage of early drug discovery.